ERBB2 and breast carcinoma: In China, the inclusion of Trastuzumab in the national reimbursement drug list allowed for a reduction in its price through bulk purchasing mechanisms, significantly increasing its utilization among HER2 + breast cancer patients and lowering their out-of-pocket costs.